Results 151 to 160 of about 5,806,183 (351)

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Protocol for in vivo fluorescence lifetime microendoscopic imaging of the murine femoral marrow

Methods in Microscopy
We present a protocol for micro-endoscopic fluorescence lifetime imaging in the femoral marrow of mice allowing the analysis of NAD(P)H-dependent metabolism at single cell level, in vivo.
Fiedler Alexander F., Niesner Raluca A.
doaj   +1 more source

DOES KETAMINE METABOLITE II EXIST IN VIVO ?

, 1981
P. Stenberg, Jan Idvall
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Reply to In vivo confusion over in vivo conversion

Molecular Therapy, 2022
Lei-Lei Wang, Chun-Li Zhang
openaire   +2 more sources

Studies on In Vivo Formation of Nitroso Compounds (I)

, 1975
Motoo Harada, Hajimu ISHIWATA, Yoko Nakamura, Akio TANIMURA, Morizo Ishidate   +4 more
openalex   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Semi-in-vivo ? [PDF]

Nature, 1971
openaire   +2 more sources

In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma [PDF]

Felix Korell, Nelson H. Knudsen, Tamina Kienka, Giulia Escobar, Celeste Nobrega, Seth Anderson, Andrew Y. Cheng, Maria Zschummel, Amanda A. Bouffard, Michael C. Kann, S Goncalves, Hans W. Pope, Mohammad Zakaria Pezeshki, Alexánder Rojas, Juliette S. M. T. Suermondt, Merle Phillips, Trisha R. Berger, Sangwoo Park, Diego Salas‐Benito, Elijah P. Darnell, Filippo Birocchi, Mark B. Leick, Rebecca C. Larson, John G. Doench, Dipankar Sen, Kathleen B. Yates, Robert T. Manguso, Marcela V. Maus   +27 more
openalex   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source